2025-10-05 - Analysis Report
Okay, here's an analysis of Teladoc Health Inc. (TDOC) based on the provided information, formatted as requested.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** TDOC
*   **Company:** Teladoc Health Inc. (Teladoc Health is a virtual healthcare company that offers telehealth services.)

**Key Metrics:**

*   TDOC Cumulative Return: -56.65%
*   VOO Cumulative Return: 99.54%
*   Absolute Divergence (TDOC - VOO): -158.7
*   Divergence Range: Min: -162.5, Max: 312.6
*   Relative Divergence: 0.8

**Analysis:**

The provided data highlights a significant underperformance of TDOC compared to the S&P 500 (VOO). The cumulative return difference is substantial (-158.7%). The relative divergence of 0.8 indicates that TDOC's underperformance is near the lowest end of its historical range relative to VOO.

**Alpha/Beta Analysis Table:**

| Year       | CAGR     | MDD      | Alpha    | Beta    | Cap (B) |
| :----------- | :------- | :------- | :------- | :------ | :------ |
| 2015-2017  | 77.0%    | 70.4%    | 51.0%    | -0.1    | 6.2     |
| 2016-2018  | 101.0%   | 69.4%    | 86.0%    | -0.1    | 8.8     |
| 2017-2019  | 141.0%   | 73.8%    | 118.0%   | 0.3     | 14.8    |
| 2018-2020  | 105.0%   | 80.9%    | 81.0%    | 0.3     | 35.3    |
| 2019-2021  | -78.0%   | 80.9%    | -125.0%  | 0.3     | 16.2    |
| 2020-2022  | -252.0%  | 85.9%    | -251.0%  | -0.9    | 4.2     |
| 2021-2023  | -315.0%  | 85.9%    | -316.0%  | -1.8    | 3.8     |
| 2022-2024  | -93.0%   | 85.9%    | -113.0%  | -1.9    | 1.6     |
| 2023-2025  | -28.0%   | 81.6%    | -91.0%   | -0.8    | 1.6     |

**Analysis:**

*   **Early Growth (2015-2020):**  Strong CAGR and positive Alpha indicate significant outperformance relative to the market. Beta values are relatively low.
*   **Recent Struggles (2019-2025):**  Negative CAGR, large negative Alpha values, and negative Beta suggest significant underperformance, indicating the stock is performing worse than the market and is negatively correlated with it. Maximum Drawdown (MDD) remains high, indicating significant volatility.  Capitalization (Cap) has decreased substantially, reflecting the decline in the company's market value.

**2. Recent Price Action**

*   Current Price: 9.01
*   Previous Close: 8.48
*   Change: 6.25%
*   5-day Moving Average: 8.173
*   20-day Moving Average: 8.0105
*   60-day Moving Average: 7.7514

**Analysis:**

The stock shows a strong upward movement with a 6.25% increase and the price is currently above all three moving averages (5-day, 20-day, and 60-day). This suggests a short-term bullish trend.

**3. Technical Indicators and Expected Return**

*   Market Risk Indicator (MRI): 0.9 (High Investment Recommended)
*   RSI: 67.87
*   PPO: 0.67
*   Hybrid Signal: Cash 0%, Buy 100% (110 shares) - Very Safe - MRI: 0.9
*   Recent (20-day) Relative Divergence Change: 0.4 (+) - Short-term increase
*   Expected Return (%): -9445.0 (Long-term, vs. S&P 500)

**Analysis:**

*   **MRI:** A high MRI (0.9) suggests that the investment is considered relatively safe based on the model.
*   **RSI:** The RSI of 67.87 is approaching overbought territory (typically above 70).
*   **PPO:** A positive PPO indicates that the short-term moving average is above the long-term moving average, suggesting upward momentum.
*   **Hybrid Signal:** The signal recommends buying 100% of available cash, indicating a bullish outlook based on the MRI.
*   **Recent Price Jump:** The significant change in price (6.25%) suggests a recent event or news has triggered a substantial reaction in the market.
*   **Expected Return:** The extremely negative expected return (-9445.0%) is unrealistic and likely an error in the data or calculation. It should not be used for investment decisions.

**4. Recent News & Significant Events**

*   **Positive Catalysts:** Several articles highlight positive catalysts, including a 15% jump in stock price ("Why Teladoc Health Stock Jumped 15% This Morning"), and mentions of Teladoc in lists of stocks that are "skyrocketing" ("Etsy, Snap, The RealReal, Instacart, and Teladoc Shares Skyrocket").
*   **Contradictory Signals:** Other articles present a more cautious view, questioning whether Teladoc is a value trap ("Down 96% From Its Highs, Is Teladoc a Hidden Bargain or a Value Trap?"). There are also mentions in lists of "small-cap stocks that concern us".
*   **Short Seller Sentiment:** An article mentions short sellers still believing their day will come.

**4-2. Analyst Opinions**

*   Consensus: Hold
*   Mean Rating: 2.64 (~Hold)
*   Number of Opinions: 20
*   Target Price: Avg: 9.12 / High: 12.00 / Low: 7.00
*   Recent Rating Changes: Not specified

**Analysis:**

Analyst opinions are neutral, with a consensus rating of "Hold". The average target price is slightly above the current price.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
| :--------- | :---- | :-------- |
| 2025-07-30 | -0.19 | 0.63 B$   |
| 2025-05-01 | -0.53 | 0.63 B$   |
| 2024-10-31 | -0.19 | 0.64 B$   |
| 2024-08-01 | -4.92 | 0.64 B$   |
| 2025-07-30 | -4.92 | 0.64 B$   |

**Analysis:**

*   **EPS:** Recent EPS figures are generally negative.  There was a significant loss in 2024-08-01 and 2025-07-30 (-4.92), with more recent quarters showing smaller losses (-0.19, -0.53).
*   **Revenue:** Revenue has been relatively stable around $0.63-0.64 billion.

**6. Financial Information**

Revenue and Profitability:

| Quarter    | Revenue | Profit Margin |
| :--------- | :------ | :------------ |
| 2025-06-30 | $0.63B  | 69.85%        |
| 2025-03-31 | $0.63B  | 68.73%        |
| 2024-12-31 | $0.64B  | 70.50%        |
| 2024-09-30 | $0.64B  | 71.94%        |
| 2024-06-30 | $0.64B  | 70.73%        |

Capital and Profitability:

| Quarter    | Equity    | ROE       |
| :--------- | :-------- | :-------- |
| 2025-06-30 | $1.42B    | -2.30%    |
| 2025-03-31 | $1.43B    | -6.52%    |
| 2024-12-31 | $1.49B    | -3.25%    |
| 2024-09-30 | $1.51B    | -2.21%    |
| 2024-06-30 | $1.50B    | -55.77%   |

**Analysis:**

*   **Revenue & Profit Margin:** Revenue is consistent.  Profit margins are relatively high.
*   **Equity & ROE:** Equity has been slightly decreasing. ROE is negative, indicating the company is not generating profits from its equity.

**7. Overall Summary**

TDOC has significantly underperformed the S&P 500. While recent price action shows a strong upward trend, driven by news catalysts, the long-term picture remains concerning. The company has struggled with profitability (negative EPS and ROE), despite maintaining relatively stable revenue and high profit margins. Analyst opinions are neutral, and the negative long-term expected return should raise caution.

**Investment Recommendation:**

Based on this analysis, a cautious approach is warranted. While the recent price jump and positive MRI might tempt some investors, the negative fundamentals and long-term underperformance suggest a high degree of risk. Further research is needed to understand the reasons behind the persistent losses and to evaluate the company's future prospects.
